| Head and neck cancer A Argiris, MV Karamouzis, D Raben, RL Ferris The Lancet 371 (9625), 1695-1709, 2008 | 2572 | 2008 |
| Carboplatin and paclitaxel in combination with either vorinostat or placebo for first-line therapy of advanced non–small-cell lung cancer SS Ramalingam, ML Maitland, P Frankel, AE Argiris, M Koczywas, ... Journal of Clinical Oncology 28 (1), 56-62, 2010 | 301 | 2010 |
| CTLA-4+ Regulatory T Cells Increased in Cetuximab-Treated Head and Neck Cancer Patients Suppress NK Cell Cytotoxicity and Correlate with Poor Prognosis HB Jie, PJ Schuler, SC Lee, RM Srivastava, A Argiris, S Ferrone, ... Cancer research 75 (11), 2200-2210, 2015 | 280 | 2015 |
| Swallowing dysfunction—preventative and rehabilitation strategies in patients with head-and-neck cancers treated with surgery, radiotherapy, and chemotherapy: a critical review BB Mittal, BR Pauloski, DJ Haraf, HJ Pelzer, A Argiris, EE Vokes, ... International Journal of Radiation Oncology* Biology* Physics 57 (5), 1219-1230, 2003 | 274 | 2003 |
| The impact of health insurance status on the survival of patients with head and neck cancer J Kwok, SM Langevin, A Argiris, JR Grandis, WE Gooding, E Taioli Cancer: Interdisciplinary International Journal of the American Cancer …, 2010 | 263 | 2010 |
| Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): An update on 107 randomized trials and 19,805 patients, on behalf of MACH-NC Group B Lacas, A Carmel, C Landais, SJ Wong, L Licitra, JS Tobias, B Burtness, ... Radiotherapy and Oncology 156, 281-293, 2021 | 261 | 2021 |
| Competing causes of death and second primary tumors in patients with locoregionally advanced head and neck cancer treated with chemoradiotherapy A Argiris, BE Brockstein, DJ Haraf, KM Stenson, BB Mittal, MS Kies, ... Clinical cancer research 10 (6), 1956-1962, 2004 | 245 | 2004 |
| Myeloid-derived suppressor cell measurements in fresh and cryopreserved blood samples A Kotsakis, M Harasymczuk, B Schilling, V Georgoulias, A Argiris, ... Journal of immunological methods 381 (1-2), 14-22, 2012 | 233 | 2012 |
| Phase I and pharmacokinetic study of vorinostat, a histone deacetylase inhibitor, in combination with carboplatin and paclitaxel for advanced solid malignancies SS Ramalingam, RA Parise, RK Ramananthan, TF Lagattuta, ... Clinical cancer research 13 (12), 3605-3610, 2007 | 233 | 2007 |
| Phase III randomized, placebo-controlled trial of docetaxel with or without gefitinib in recurrent or metastatic head and neck cancer: an eastern cooperative oncology group trial A Argiris, M Ghebremichael, J Gilbert, JW Lee, K Sachidanandam, ... Journal of Clinical Oncology 31 (11), 1405-1414, 2013 | 232 | 2013 |
| Therapies directed against epidermal growth factor receptor in aerodigestive carcinomas MV Karamouzis, JR Grandis, A Argiris Jama 298 (1), 70-82, 2007 | 221 | 2007 |
| Prognostic factors and long‐term survivorship in patients with recurrent or metastatic carcinoma of the head and neck: An analysis of two Eastern Cooperative Oncology Group … A Argiris, Y Li, A Forastiere Cancer: Interdisciplinary International Journal of the American Cancer …, 2004 | 215 | 2004 |
| Evaluating the supportive care costs of severe radiochemotherapy‐induced mucositis and pharyngitis: results from a northwestern university costs of cancer program pilot study … NJ Nonzee, NA Dandade, T Markossian, M Agulnik, A Argiris, JD Patel, ... Cancer: Interdisciplinary International Journal of the American Cancer …, 2008 | 195 | 2008 |
| Stereotactic body radiotherapy for recurrent squamous cell carcinoma of the head and neck: results of a phase I dose-escalation trial DE Heron, RL Ferris, M Karamouzis, RS Andrade, EL Deeb, S Burton, ... International Journal of Radiation Oncology* Biology* Physics 75 (5), 1493-1500, 2009 | 191 | 2009 |
| Evidence-based treatment options in recurrent and/or metastatic squamous cell carcinoma of the head and neck A Argiris, KJ Harrington, M Tahara, J Schulten, P Chomette, ... Frontiers in oncology 7, 72, 2017 | 185 | 2017 |
| A phase II study of AT-101 (Gossypol) in chemotherapy-sensitive recurrent extensive-stage small cell lung cancer MQ Baggstrom, Y Qi, M Koczywas, A Argiris, EA Johnson, MJ Millward, ... Journal of Thoracic Oncology 6 (10), 1757-1760, 2011 | 185 | 2011 |
| Phase I dendritic cell p53 peptide vaccine for head and neck cancer PJ Schuler, M Harasymczuk, C Visus, A DeLeo, S Trivedi, Y Lei, A Argiris, ... Clinical Cancer Research 20 (9), 2433-2444, 2014 | 183 | 2014 |
| Neck dissection in the combined‐modality therapy of patients with locoregionally advanced head and neck cancer A Argiris, KM Stenson, BE Brockstein, BB Mittal, H Pelzer, MS Kies, ... Head & Neck: Journal for the Sciences and Specialties of the Head and Neck …, 2004 | 173 | 2004 |
| Staging and clinical prognostic factors for small-cell lung cancer. A Argiris, JR Murren Cancer journal (Sudbury, Mass.) 7 (5), 437-447, 2001 | 171 | 2001 |
| Cetuximab and bevacizumab: preclinical data and phase II trial in recurrent or metastatic squamous cell carcinoma of the head and neck A Argiris, AP Kotsakis, T Hoang, FP Worden, P Savvides, MK Gibson, ... Annals of oncology 24 (1), 220-225, 2013 | 167 | 2013 |
